December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

DexCom, Inc. - Common Stock (NQ:DXCM)

72.63 +0.36 (+0.50%)
Streaming Delayed Price Updated: 2:40 PM EST, Feb 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about DexCom, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
46 47 Next >
News headline image
The 5 Most Interesting Analyst Questions From DexCom’s Q4 Earnings Call
DexCom’s fourth quarter results reflected ongoing momentum in both product innovation and international expansion. Management attributed the quarter’s performance to the broad rollout of the G7 15-day... 
Via StockStory
Topics Earnings
News headline image
Insulet (PODD) Shakes the Market with Q4 Earnings Beat as Omnipod 5 Dominance Continues
Insulet Corporation (NASDAQ:PODD) delivered a commanding performance in its fourth-quarter earnings report released today, February 18, 2026. The medical device leader announced an adjusted earnings... 
Via MarketMinute
Topics Earnings
Dexcom Inc (NASDAQ:DXCM) Beats Q4 Profit Estimates Despite Revenue Shortfall ↗
Via Chartmill
DexCom Inc. (NASDAQ:DXCM) Combines Strong Fundamentals with Bullish Chart Pattern ↗
Via Chartmill
Top S&P500 movers in Friday's session ↗
Via Chartmill
Friday's session: top gainers and losers in the S&P500 index ↗
Via Chartmill
News headline image
Why Is DexCom (DXCM) Stock Rocketing Higher Today
Shares of medical device company DexCom (NASDAQ:DXCM) jumped 7.3% in the morning session after it reported better-than-expected fourth-quarter 2025 financial results, beating analyst estimates for both... 
Via StockStory
Topics Artificial Intelligence Supply Chain
News headline image
Soleus Adds a Significant Number of Celcuity Shares ↗
This clinical-stage biotech develops targeted cancer therapies and diagnostics using proprietary technology for personalized treatment. 
Via The Motley Fool
News headline image
DXCM Q4 Deep Dive: New Product Launches and International Strategy Drive Outlook
Medical device company DexCom (NASDAQ:DXCM) reported Q4 CY2025 results beating Wall Street’s revenue expectations, with sales up 13.1% year on year to $1.26 billion. The company expects the full year’s... 
Via StockStory
News headline image
DexCom (DXCM) Q4 2025 Earnings Call Transcript ↗
DexCom (DXCM) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings Economy
News headline image
DexCom (NASDAQ:DXCM) Exceeds Q4 CY2025 Expectations
Medical device company DexCom (NASDAQ:DXCM) announced better-than-expected revenue in Q4 CY2025, with sales up 13.1% year on year to $1.26 billion. The company expects the full year’s revenue to be... 
Via StockStory
News headline image
Dexcom Reports Fourth Quarter and Fiscal Year 2025 Financial Results
From DexCom, Inc.
Via Business Wire
News headline image
Earnings To Watch: DexCom (DXCM) Reports Q4 Results Tomorrow
Medical device company DexCom (NASDAQ:DXCM) will be reporting earnings this Thursday after market hours. Here’s what you need to know. 
Via StockStory
Topics Artificial Intelligence
News headline image
1 High-Flying Stock with Impressive Fundamentals and 2 We Ignore
"You get what you pay for" often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the premium, they typically experience elevated... 
Via StockStory
News headline image
1 Cash-Producing Stock Worth Your Attention and 2 Facing Headwinds
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. 
Via StockStory
News headline image
Stelo Adds Enhanced Smart Meal Logging Features as Dexcom Continues to Transform Personal Glucose Management
From Dexcom, Inc.
Via Business Wire
News headline image
3 Profitable Stocks for Long-Term Investors
Profitability is a key measure of business strength. Companies with high margins have proven they can generate consistent earnings while maintaining financial discipline. 
Via StockStory
News headline image
Dexcom Schedules Fourth Quarter and Fiscal Year 2025 Earnings Release and Conference Call for February 12, 2026 at 4:30 p.m. Eastern Time.
From DexCom, Inc.
Via Business Wire
News headline image
2 Mid-Cap Stocks with Exciting Potential and 1 We Ignore
Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. However, they face intense competition from... 
Via StockStory
News headline image
Abbott Laboratories Shares Plunge 10% Following Q4 Revenue Miss and Diagnostics Weakness
Abbott Laboratories (NYSE: ABT) saw its stock price tumble by nearly 10% in early trading on January 22, 2026, following the release of its fourth-quarter 2025 financial results. Despite meeting... 
Via MarketMinute
Topics Economy
News headline image
Abbott Shares Slump as Revenue Miss and Exact Sciences Acquisition Jitters Overshadow Earnings Beat
Abbott Laboratories (NYSE: ABT) saw its shares retreat by 5.8% in early trading on Thursday, January 22, 2026, following the release of its fourth-quarter financial results. Despite delivering an... 
Via MarketMinute
Topics Earnings Economy
News headline image
1 Growth Stock Down 19% to Buy Right Now ↗
It has had strong momentum since November, but there is still plenty of upside left. 
Via The Motley Fool
Topics Product Recall
News headline image
Halper Sadeh LLC Encourages DexCom, Inc. Shareholders to Contact the Firm to Discuss Their Rights
From Halper Sadeh LLC
Via Business Wire
Top S&P500 movers in Monday's session ↗
Via Chartmill
What's going on in today's session: S&P500 movers ↗
Via Chartmill
News headline image
Dexcom Reports Preliminary, Unaudited Results for the Fourth Quarter and Fiscal Year 2025 and Initial 2026 Outlook
From DexCom, Inc.
Via Business Wire
News headline image
DexCom (DXCM) Stock Trades Down, Here Is Why
Shares of medical device company DexCom (NASDAQ:DXCM) fell 2.6% in the morning session after analysts at Piper Sandler and Bernstein lowered their price targets on the stock, citing concerns over the... 
Via StockStory
Topics Artificial Intelligence
News headline image
Dexcom Enters Next Era of Continued Innovation With Jake Leach as President and Chief Executive Officer
From DexCom, Inc.
Via Business Wire
News headline image
3 Nasdaq 100 Stocks Worth Your Attention
The Nasdaq 100 (^NDX) is where investors find some of the most innovative and disruptive companies shaping the future. A select few continue to execute at a high level, growing their market dominance... 
Via StockStory
News headline image
The Evolution of a Healthcare Giant: Abbott Laboratories (ABT) 2026 Stock Feature
As of today, January 1, 2026, Abbott Laboratories (NYSE: ABT) stands as one of the most resilient and strategically diversified giants in the global healthcare landscape. While the broader market has... 
Via PredictStreet
Topics Economy Lawsuit World Trade
< Previous 1 2 3 4 5 6 7 8 9
...
46 47 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.